On August 12, Jiangsu Yuyue Medical Equipment Co., Ltd. (hereinafter referred to as “Yuyue Medical”, 002223.SZ) released the 2021 semi -annual report. The net profit of shareholders of listed companies was 963 million yuan, a year -on -year decrease of 13.99%.

The semi -annual report shows that the main reason for the decline in net profit is that the company’s product sales accounted for the epidemic situation in the same period of 2020, which was greatly affected by the epidemic situation, and there was a certain difference in overall gross profit levels. During the reporting period, Yuyue Medical achieved a gross profit margin of 50.48%, an increase of 8.81%year -on -year in the first half of 2019. Some people in the industry pointed out that due to the epidemic factors, the sales structure of Yuyue Medical Products in the first half of 2020 is large, so the gross profit margin of sales will be relatively accurate from 2019.

Yuyue Medical products are mainly concentrated in respiratory oxygen, diabetic care, infection control solutions, home electronic detection and in vitro diagnosis, emergency and clinical and rehabilitation equipment, and clarify respiratory, blood sugar and home POCT (instant detection) The three core growth tracks of disinfection sensing, in addition, further layout of incubation business such as first aid, ophthalmology, and intelligent rehabilitation.

鱼跃医疗看好家用POCT赛道,血糖仪市场比拼“准确性”

Yuyue Medical sales staff told First Financial reporters that among them, the layout of breathing and disinfection sensing is mainly affected by the epidemic. At the current growth of blood glucose and home POCT (instant detection) sector, the growth rate of blood glucose products is relatively faster. During the reporting period, the business scale of diabetes -related products increased by more than 120% compared with the same period of 2020

“Medical POCT is very different from home POCT. POCT medical institutions with a number of testing projects are used more, and the household POCT does well include electronic sphygmomanometer and blood glucose meter.” The above sales staff said.

“In the morning, blood glucose and blood sugar testing after meals are meaningful, and it is not necessary to go to pharmacies in these two periods. The awareness rate of domestic blood glucose measurement at the current population of large cities is not low. Price, brand, customer acquisition ability and customer trust, specifically to reduce consumable price, increase service awareness, attract users to continue to use, and self -manage blood sugar. “Some person in charge of home medical equipment companies told First Financial reporters.

Since the home POCT and the hospital are not a sales and service system with POCT, their prices, channels, marketing strategies, and target user bases are different, and manufacturers will treat them differently.

The above -mentioned person in charge believes that the hospital has also wanted to use POCT companies as C -terminal users, but it is not successful. It is a big test to do B -end and C -ends at the same time. The home blood glucose meter companies mainly include Yuyue Medical and Sannuo Bio (300298.SZ), and imported brands such as Johnson & Johnson and Abbott have also been in operation for many years. The accuracy, stability improvement and price competitiveness of domestic blood glucose instrument products will gradually occupy greater market share. There are also new types of household non -invasive and non -consumables and sugar measurement methods. As the price of new technologies decreases, it may have a certain impact on the blood glucose instrument market.

It is understood that the largest market size of the home blood glucose meter is Beijing Yicheng Biological Electronic Technology Co., Ltd., which launched the first home fast blood glucose meter in 1995. In 2004, Sannuo creatures entered the blood glucose market. In addition, Aikang Biological and Lepu Medical also involved blood glucose -related products.

In the first half of 2021, Yuyue Medical initiated the acquisition of 50.993%of the equity of Zhejiang Kailitter Medical Device Co., Ltd. (hereinafter referred to as “Kaitit”). Founded in 2010, Kailite is committed to research and development, production and sales of medical portable monitoring systems with high -end biosensors as its core technology, including dynamic blood glucose monitoring and other POCT instant inspection products, and provides comprehensive, effective and economic diabetes management Program.

According to data released by the International Diabetes Alliance, there are more than 100 million domestic diabetic diagnosis patients in 2019. It is expected that domestic diabetic people will reach 200 million in 2030, and the demand for blood glucose management markets is huge. Yuyue Medical has mentioned that relying on Kaylit’s R & D team and technology in the field of diabetes and sensor technology, it is conducive to the company’s complete business layout in the diabetes track.

You might also enjoy: